Connect with us

Hi, what are you looking for?

Friday, Sep 22, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


FDA publishes first draft guidance document for psychedelics research

It aims to highlight relevant considerations for researchers investigating the therapeutic value of psychedelics

U.S. FDA publishes first draft guidance document for clinical trials involving psychedelics
Optimi Health's GMP-certified psilocybin mushrooms used to supply clinical trials. Photo by Rowan Dunne

Amidst the growing interest in the potential health benefits of psychedelic drugs, the United States Food and Drug Administration (FDA) has published its first document outlining fundamental considerations for researchers involved in their study.

The document published on Friday aims to help address the challenges associated with clinical studies involving these substances following a growing body of research emerging about their potential for treating everything from PTSD and depression to cocaine and alcohol use disorders. The FDA is seeking public feedback regarding the new document for the next 60 days.

“By publishing this draft guidance, the FDA hopes to outline the challenges inherent in designing psychedelic drug development programs and provide information on how to address these challenges,” said Tiffany Farchione, Director of the FDA Center for Drug Evaluation and Research’s Division of Psychiatry.

She says despite the potential psychedelics have shown for the treatment of substance use, anxiety, and mood disorders, they are still products in an investigational phase.

“The goal is to help researchers design studies that will yield interpretable results that will be capable of supporting future drug applications,” she added.

Read more: Neuma and St. Lawrence college pioneer psychedelic exploration program for community wellness

Read more: Psycheceutical Bioscience develops non-psychoactive ketamine topical for PTSD and depression

With regard to the term “psychedelics,” the FDA says it is primarily referring to drugs that influence the brain’s serotonin system like psilocybin and LSD and empathogens like MDMA.

“This guidance applies to clinical trials that will be conducted under an investigational new drug application (IND), including such clinical trials [e.g., research or academic studies] that are not intended to support marketing applications,” reads the new document.

The document says psychedelic drugs that lack an adequate history of clinical exposure should not be tested in humans until their safety has been sufficiently established in non-clinical studies and that those drugs should be assessed for their abuse potential among users as well.

Despiting being the organization’s first draft guidance, the document is quite comprehensive and outlines considerations such as proper data collection and trial conduct among other things.

The news follows the United States making a number of significant strides with psychedelics research in recent days, such as the government of Kentucky investing US$42 million in psychedelics research for the treatment of opioid use disorders this month and Ohio State University receiving approval from the U.S. Drug Enforcement Administration to cultivate and research psilocybin mushrooms in May.


Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


It now has 19 million shares of the psychedelic drug developer, the firm's first investment in a public entity of this variety


The study findings represent the culmination of more than two decades of dedicated research efforts


Funds will be used to study psilocybin and MDMA-assisted therapy; non-profit says Sweden needs to 'catch up' in this area of research


Silo's SPC-15 was developed in collaboration with Columbia University